Thomas A Baillie

发表

Negative ion tandem mass spectrometry for the detection of glutathione conjugates.

Richard King, T. Baillie, C. Dieckhaus, 2005, Chemical research in toxicology.

Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology.

T. Baillie, Thomas A Baillie, 2006, Chemical research in toxicology.

Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions.

T. Baillie, Sanjeev Kumar, Thomas A Baillie, 2008, Current opinion in drug discovery & development.

Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites.

Thomayant Prueksaritanont, T. Baillie, T. Prueksaritanont, 2006, Toxicology and applied pharmacology.

Addressing Metabolic Activation as an Integral Component of Drug Design

T. Baillie, G. Doss, George A Doss, 2006, Drug metabolism reviews.

Organic Chemistry in Drug Discovery

T. Baillie, M. Maccoss, Malcolm MacCoss, 2004, Science.

Bridging cheminformatic metabolite prediction and tandem mass spectrometry.

T. Baillie, Thomas A Baillie, M Reza Anari, 2005, Drug discovery today.

Drug metabolites in safety testing.

T. Baillie, M. Cayen, L. Shipley, 2002, Toxicology and applied pharmacology.

Targeted Covalent Inhibitors for Drug Design.

T. Baillie, Thomas A Baillie, 2016, Angewandte Chemie.

Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation.

T. Baillie, Wei Tang, G. Doss, 2002, Chemical research in toxicology.

Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism.

T. Baillie, Thomas A Baillie, 2008, Chemical research in toxicology.

High-throughput, accurate mass liquid chromatography/tandem mass spectrometry on a quadrupole time-of-flight system as a 'first-line' approach for metabolite identification studies.

Sean Yu, T. Baillie, J. Castro-Pérez, 2008, Rapid communications in mass spectrometry : RCM.

EVIDENCE FOR THE BIOACTIVATION OF ZOMEPIRAC AND TOLMETIN BY AN OXIDATIVE PATHWAY: IDENTIFICATION OF GLUTATHIONE ADDUCTS IN VITRO IN HUMAN LIVER MICROSOMES AND IN VIVO IN RATS

David C Evans, T. Baillie, M. Braun, 2006, Drug Metabolism and Disposition.

Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins.

T. Baillie, P. Pearson, B. Wong, 2003, Chemical research in toxicology.

EVALUATION OF MICRODOSING STRATEGIES FOR STUDIES IN PRECLINICAL DRUG DEVELOPMENT: DEMONSTRATION OF LINEAR PHARMACOKINETICS IN DOGS OF A NUCLEOSIDE ANALOG OVER A 50-FOLD DOSE RANGE

M. P. Baker, T. Baillie, J. Vogel, 2004, Drug Metabolism and Disposition.

Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development.

T. Baillie, Thomas A Baillie, David C. Evans, 2004, Chemical research in toxicology.

Fractional mass filtering as a means to assess circulating metabolites in early human clinical studies.

Sean Yu, Kevin P Bateman, T. Baillie, 2008, Rapid communications in mass spectrometry : RCM.